99 related articles for article (PubMed ID: 7591249)
1. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma.
Ehrke MJ; Verstovsek S; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Mihich E
Int J Cancer; 1995 Nov; 63(3):463-71. PubMed ID: 7591249
[TBL] [Abstract][Full Text] [Related]
2. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation.
Ehrke MJ; Verstovsek S; Pocchiari SK; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Meer JM; Mihich E
Int J Cancer; 1998 May; 76(4):579-86. PubMed ID: 9590137
[TBL] [Abstract][Full Text] [Related]
3. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice.
Ehrke MJ; Verstovsek S; Maccubbin DL; Ujházy P; Zaleskis G; Berleth E; Mihich E
Int J Cancer; 2000 Jul; 87(1):101-9. PubMed ID: 10861459
[TBL] [Abstract][Full Text] [Related]
4. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2.
Ehrke MJ; Verstovsek S; Zaleskis G; Ho RL; Ujházy P; Maccubbin DL; Mihich E
Cancer Immunol Immunother; 1996 May; 42(4):221-30. PubMed ID: 8665569
[TBL] [Abstract][Full Text] [Related]
5. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.
Krawczyk CM; Verstovsek S; Ujházy P; Maccubbin D; Ehrke MJ
Cancer Immunol Immunother; 1995 Jun; 40(6):347-57. PubMed ID: 7627991
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.
Ehrke MJ; Verstovsek S; Ujházy P; Meer JM; Eppolito C; Maccubbin DL; Mihich E
Cancer Immunol Immunother; 1998 Feb; 45(6):287-98. PubMed ID: 9490198
[TBL] [Abstract][Full Text] [Related]
8. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
[TBL] [Abstract][Full Text] [Related]
9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
10. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo.
Kaneko H; Hori T; Yanagita S; Kadowaki N; Uchiyama T
Exp Hematol; 2005 Mar; 33(3):336-43. PubMed ID: 15730857
[TBL] [Abstract][Full Text] [Related]
11. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
Kaido T; Maury C; Schirrmacher V; Gresser I
Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
13. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide eradicates murine immunogenic tumor coding for a non-self-antigen and induces antitumor immunity.
Salem ML; El-Naggar SA; Mahmoud HA; Elgharabawy RM; Bader AM
Int J Immunopathol Pharmacol; 2018; 32():2058738418796591. PubMed ID: 30270681
[TBL] [Abstract][Full Text] [Related]
15. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
16. Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide.
Tzai TS; Lin JS; Chow NH
J Surg Res; 1996 Oct; 65(2):139-44. PubMed ID: 8903460
[TBL] [Abstract][Full Text] [Related]
17. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
Ho RL; Maccubbin D; Zaleskis G; Krawczyk C; Wing K; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
[TBL] [Abstract][Full Text] [Related]
18. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
[TBL] [Abstract][Full Text] [Related]
19. Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
Selvan RS; Nagarkatti PS; Nagarkatti M
Int J Cancer; 1990 Jun; 45(6):1096-104. PubMed ID: 1972141
[TBL] [Abstract][Full Text] [Related]
20. Effect of perioperative chemoimmunotherapy with cyclophosphamide and autologous tumor vaccine in murine MBT-2 bladder cancer.
Tzai TS; Huben RP; Zaleskis G; Berleth ES; Ehrke MJ; Mihich E
J Urol; 1994 Jun; 151(6):1680-6. PubMed ID: 8189597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
